Data shows Cladribine benefits persist in RRMS patients
Posted: Tue Apr 19, 2016 4:33 am
The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a study presented at the 68th American Academy of Neurology Annual Meeting...Read More - http://www.ms-uk.org/MSnews